<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03048019</url>
  </required_header>
  <id_info>
    <org_study_id>17-2617</org_study_id>
    <nct_id>NCT03048019</nct_id>
  </id_info>
  <brief_title>Comparison of Pharmacodynamic Effects of Tirofiban vs. Cangrelor in N-STEMI Patients Undergoing Percutaneous Coronary Intervention</brief_title>
  <official_title>Comparison of Pharmacodynamic Effects of Tirofiban vs. Cangrelor in N-STEMI Patients Undergoing Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inova Health Care Services</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inova Health Care Services</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Immediate potent inhibition of platelet function is critical for the prevention of&#xD;
      periprocedural ischemic event occurrences in high risk N-ST segment elevation myocardial&#xD;
      infarction (NSTEMI) in patients undergoing percutaneous coronary intervention (PCI).&#xD;
      Currently, dual antiplatelet therapy with aspirin and an oral P2Y12 receptor blocker (with&#xD;
      loading doses) is widely used for PCI. However, immediate, potent and reversible inhibition&#xD;
      of platelet aggregation is not possible even with the newer oral agents, prasugrel and&#xD;
      ticagrelor. Therefore, an intravenously administered GPIIb/IIIa receptor inhibitor&#xD;
      (tirofiban) or P2Y12 receptor blocker (cangrelor) with fast onset and offset of actions will&#xD;
      provide more desired antiplatelet effects in the setting of PCI. This study will measure and&#xD;
      compare the anti-platelet effects of Tirofiban and Cangrelor in patients presenting with&#xD;
      N-STEMI and undergoing PCI.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">August 23, 2017</start_date>
  <completion_date type="Anticipated">May 29, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of platelet aggregation in response to thrombin receptor activator peptide (TRAP) at baseline and serially following tirofiban or cangrelor infusion.</measure>
    <time_frame>24 hrs</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of platelet aggregation in response to ADP and collagen at baseline and serially following tirofiban or cangrelor infusion.</measure>
    <time_frame>24 hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of platelet aggregation (ADP-induced) and thrombin induced platelet-fibrin clot strength by Thrombelastography (TEG6S)</measure>
    <time_frame>24 hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of thrombin generation by Calibrated Automated Thrombogram (CAT).</measure>
    <time_frame>24 hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of annexin binding and p-selectin expression by flow cytometry</measure>
    <time_frame>24 hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Real time evaluation of shear-induced thrombus formation using novel RUO T-TAS plus system.</measure>
    <time_frame>24 hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of High-Sensitivity Troponin biomarker</measure>
    <time_frame>24 hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of CK-MB biomarker</measure>
    <time_frame>24 hr</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Non-ST Elevation Myocardial Infarction (NSTEMI)</condition>
  <arm_group>
    <arm_group_label>Tirofiban Therapy</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Cangrelor Therapy</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tirofiban</intervention_name>
    <description>Patients will receive Tirofiban during the PCI procedure</description>
    <arm_group_label>Tirofiban Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cangrelor</intervention_name>
    <description>Patients will receive Cangrelor during the PCI procedure</description>
    <arm_group_label>Cangrelor Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This study will consist of NSTEMI patients undergoing percutaneous coronary intervention&#xD;
        (PCI): 30 patients each will be treated with tirofiban or cangrelor (total n=60).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. NSTEMI meeting the following criteria:&#xD;
&#xD;
          1. Patients 18 years of age or older with one or more of the following symptoms:&#xD;
&#xD;
               -  new ST-segment depression or transient elevation of at least 1 mm&#xD;
&#xD;
               -  elevations in troponin I, troponin T, or creatine kinase MB levels above ULN&#xD;
&#xD;
          2. Eligible for ticagrelor, cangrelor, aspirin, UFH, and GP IIb/IIIa inhibitor treatment.&#xD;
&#xD;
          3. Admitted at cardiac catheterization laboratory hospital or associated facility.&#xD;
&#xD;
          4. Competent mental condition to provide informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unstable angina, STEMI&#xD;
&#xD;
          2. Cardiogenic shock&#xD;
&#xD;
          3. Refractory ventricular arrhythmias&#xD;
&#xD;
          4. New York Heart Association class IV congestive heart failure&#xD;
&#xD;
          5. Cardiac arrest within 1 week of study entry&#xD;
&#xD;
          6. History of hemorrhagic or ischemic stroke, TIA, sub-arachnoid hemorrhage or&#xD;
             intracranial neoplasm, arteriovenous malformation, or aneurysm&#xD;
&#xD;
          7. Fibrinolytic therapy within 48 hours of study entry&#xD;
&#xD;
          8. Active pathological bleeding or history of bleeding diathesis&#xD;
&#xD;
          9. Severe hepatic insufficiency&#xD;
&#xD;
         10. Current peptic ulceration&#xD;
&#xD;
         11. Increased bleeding risk, per investigator judgment&#xD;
&#xD;
         12. Known anemia (hematocrit&lt;25%)/thrombocytopenia (platelet count &lt; 100,000mm3)&#xD;
&#xD;
         13. Surgery within 4 weeks before study entry or planned surgery within 2 months after&#xD;
             study entry&#xD;
&#xD;
         14. Any P2Y12 receptor inhibitor or GP IIb/IIIa inhibitor within 7 days of study entry&#xD;
&#xD;
         15. Receiving warfarin or other coumadin derivatives or NOACs within the last 10 days with&#xD;
             an INR &gt;1.5 secs or planned use during the hospitalization period&#xD;
&#xD;
         16. Contraindication to the use of ticagrelor and/or aspirin&#xD;
&#xD;
         17. Receiving or will receive oral anticoagulation or other oral antiplatelet therapy&#xD;
             (except aspirin) that cannot be safely discontinued within the next 3 months&#xD;
&#xD;
         18. Receiving daily NSAIDs or COX2 inhibitors that cannot be discontinued or anticipated&#xD;
             to require &gt;2 weeks of daily NSAIDs or COX2 inhibitors during study&#xD;
&#xD;
         19. Investigational drug in last 30 days or presently enrolled in drug/device study&#xD;
&#xD;
         20. Women of childbearing potential (post-menopausal women can be enrolled if at least 1&#xD;
             year of amenorrhea or surgically sterile)&#xD;
&#xD;
         21. Condition associated with poor treatment compliance (e.g., alcoholism, mental illness,&#xD;
             or drug dependence)&#xD;
&#xD;
         22. Inability to provide written informed consent and to understand the full meaning of&#xD;
             the informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kevin Bliden, BS, MBA</last_name>
    <phone>703-776-7702</phone>
    <email>kevin.bliden@inova.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Inova Health Care System</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Bliden, BS, MBA</last_name>
      <phone>703-776-7702</phone>
      <email>kevin.bliden@inova.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>February 7, 2017</study_first_submitted>
  <study_first_submitted_qc>February 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2017</study_first_posted>
  <last_update_submitted>February 9, 2018</last_update_submitted>
  <last_update_submitted_qc>February 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Non-ST Elevated Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tirofiban</mesh_term>
    <mesh_term>Cangrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

